273 results on '"Marsh, Judith C. W."'
Search Results
2. Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
3. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
4. Guidelines for the diagnosis and management of adult aplastic anaemia
5. Romiplostim in aplastic anaemia – another tool in the armamentarium
6. Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction
7. Terminal complement inhibition dampens the inflammation during COVID‐19
8. Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients
9. Guidelines for the diagnosis and management of aplastic anaemia
10. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA
11. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults
12. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia
13. Role of apoptosis in the pathophysiology of aplastic anemia
14. Evaluation of the haemopoietic reservoir in de novo haemolytic paroxysmal nocturnal haemoglobinuria
15. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia
16. HAEMATOLOGICAL CARE OF THE JEHOVAHʼS WITNESS PATIENT
17. Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus
18. Treatment of aplastic anaemia: first do no harm
19. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia
20. Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
21. NovelADA 2mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 ( DADA 2)
22. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag
23. Treatment options in severe aplastic anaemia
24. Deficiency of glycosylphosphatidyl inositol-anchored proteins in patients with aplastic anaemia does not affect response to immunosuppressive therapy
25. Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils
26. Myelodysplasia following aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G-CSF: evidence for the emergence of a separate clone
27. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia
28. Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation.
29. Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms
30. Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience
31. Towards the Potential Use of In Vitro Expanded Regulatory T-Cells (Tregs) in Aplastic Anemia (AA): Opportunities for Therapy
32. Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis
33. Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 (DADA2).
34. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment
35. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis
36. Telomere Length and Telomerase Assay Assist in Identifying Novel Telomere Gene Complex Mutations in a Cohort of Patients with Aplastic Anemia
37. Sweet spot for cyclophosphamide: a balancing act
38. Telomerase Gene Complex Mutations Are Common in Myelodysplastic Syndromes Patients
39. Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity
40. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome
41. Eltrombopag: a stem cell cookie?
42. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience
43. Management of the refractory aplastic anemia patient: what are the options?
44. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups
45. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK
46. Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.
47. Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN
48. HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS
49. National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03)
50. Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.